Bipartisan legislation aimed at reforming pharmacy benefit manager practices might be high on lawmakers' list of priorities, but a new report from the Brookings Institution suggests "achieving large reductions in prescription drug costs will require approaches that look beyond PBMs."
Titled "A brief look at current debates about pharmacy benefit managers," the analysis provides an overview of the business of PBMs — focusing on drug rebates, pharmacy "spread" pricing, and PBMs' profits and "vertical" relationships.
The main takeaway? "[W]hile there are problems in the market for PBM services, they likely have modest effects on the overall affordability of prescription drugs," write Brookings fellows Matthew Fiedler, Loren Adler, and Richard G. Frank.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
